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OBJECTIVES The study tested the effect of red wine on endothelial-type nitric oxide synthase (eNOS)
expression and eNOS activity in human endothelial cells.
BACKGROUND Endothelial-type nitric oxide (NO) synthase exerts vasoprotective effects. Moderate alcohol
consumption has been associated with a reduction of cardiovascular disease, and red wine
seems to offer more benefits than any other type of drink. However, the molecular basis of this
protective effect is unclear.
METHODS Human endothelial cells were treated with red wine, and eNOS messenger ribonucleic acid
(mRNA) expression was measured by RNase protection assay, eNOS protein expression by
Western blotting, and eNOS activity by RFL-6 reporter cell assay. The eNOS promoter
activity was analyzed in transfected endothelial cells; binding activities of relevant transcrip-
tion factors were determined by electrophoretic mobility shift assay.
RESULTS Incubation of endothelial cells with red wines from France upregulated eNOS mRNA and
protein expression. In contrast, red wines from Germany showed little or no effect on eNOS
expression. No significant difference in eNOS mRNA expression could be detected between
“en barrique” (matured in oak barrels) and “non-barrique” (matured in steel tanks)–produced
French red wines. Endothelial cells treated with French red wines produced up to three times
more bioactive NO than did control cells. French red wines increased the activity of the
eNOS promoter, with the essential trans-stimulated sequence being located in the proximal
326 bp of the promoter sequence. The eNOS mRNA stability was also increased by red wine.
CONCLUSIONS The increase in eNOS expression and activity brought about by red wines from France (and
probably other locations) may contribute to the beneficial effects of this beverage on the
cardiovascular system. (J Am Coll Cardiol 2003;41:471–8) © 2003 by the American
College of Cardiology Foundation
Epidemiological evidence from various disparate popula-
tions has consistently correlated daily moderate wine con-
sumption with lower mortality from cardiovascular and
cerebrovascular disease and other causes (1–4). Moderate
ethanol intake from any type of beverage improves lipopro-
tein metabolism and lowers cardiovascular mortality risk
(5,6), but wine, particularly red wine with its abundant
content of phenolic acids, polyphenols, and flavonoids,
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seems to confer additional health benefits. These include an
increase in high-density lipoprotein (HDL) cholesterol
levels and decreased oxidation of low-density lipoprotein
(LDL) cholesterol, antioxidant activity, decreased platelet
aggregation and adhesion, as well as improved
endothelium-dependent vasodilation (1,4,7,8). Many of
these effects are compatible with the action of endothelium-
derived nitric oxide (NO), implying that NO may be a
mediator of the cardiovascular protection provided by red
wine. Indeed, some studies have shown that short-term
exposure of blood vessels to red wine can promote NO
generation (9,10). Although this effect of red wine is caused
by an acute activation of endothelial-type nitric oxide
synthase (eNOS) through yet unknown mechanisms, we
hypothesized that the beneficial effects of long-term wine
consumption could involve an upregulation of eNOS ex-
pression. This would lead to moderate, but sustained,
elevations of vascular NO. The current study demonstrates
that French red wines, indeed, upregulate eNOS expression
and activity and that this involves transcriptional and
posttranscriptional mechanisms.
METHODS
Wines. Wines from different areas were investigated for
their effects on eNOS expression. German red wines:
“Dornfelder 1997” (area: Mosel, grape: Dornfelder),
“Spa¨tburgunder 1999” (Palatine, Spa¨tburgunder), “Kriegs-
heimer Rosengarten 1997” (Rhine-Hessen, Portugieser/
Dornfelder), and French red wines: “Chateau Bonnet
1997”, produced “non-barrique”; “Chateau Bonnet reserve
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1997”, produced “en barrique”; “Chateau Bellegrave 1997”,
and “Chateau de la Marechaude 1997” (Bordeaux; Cabernet
Sauvignon/Cabernet Franc/Merlot); “Chateau Cabieres
1998” (Rhone; Grenache/Syrah/Mourvedre/Cinsault);
“Chateau Rousseau 1998” and “Les Chevaliers de la Reine
1998” (L. Chevaliers; Burgundy; Pinot Noir). All wines
used contained 11.5% to 12.5% ethanol, v/v; therefore, an
ethanol solution of 12.5%, v/v, in phosphate-buffered saline
(PBS) was used as the appropriate control.
Cell culture. Both human umbilical vein endothelial cells
(HUVECs) and HUVEC-derived EA.hy 926 cells were
grown in Dulbecco’s modified Eagle’s medium as described
previously (11,12). Confluent endothelial cells were incu-
bated for the periods of time indicated with the different
wines or an ethanol solution as control. Red wines and
ethanol solution were diluted in cell culture medium to final
concentrations of 1%, 3%, or 10% (v/v), respectively. Then,
either RNA or protein was extracted or eNOS activity of
intact cells was determined.
RNase protection assay of eNOS mRNA. The eNOS
messenger ribonucleic acid (mRNA) was measured by
RNase protection assay as previously described (11,12).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA was determined in parallel for normalization. The
GAPDH probe was generated according to a previously
described procedure (11,12) using total RNA from human
A673 rhabdomyosarcoma cells and oligonucleotide primers
for GAPDH corresponding to positions 501–524 (sense)
and 582–605 (antisense) of the human GAPDH cDNA
(GenBank accession number: NM_002046). Resulting
cDNA fragments (105 bp) were cloned into the pXcm
I–TA-cloning vector (kindly provided by Dr. A. Borovkov
[13]). The protected RNA fragments of eNOS and
GAPDH were 280 nt and 108 nt, respectively.
Preparation of eNOS protein and Western blotting. For
the determination of eNOS protein expression, total protein
was isolated and Western blots were performed as previ-
ously described (11,12).
Determination of eNOS activity. Bioactive NO produced
by eNOS in EA.hy 926 cells was assayed using the stimu-
lation of soluble guanylyl cyclase in RFL-6 rat lung fibro-
blasts as previously described (11,12). Results of the RFL-6
assay were verified by measuring NO2
/NO3
 formation as
previously described (11). The EA.hy 926 cells were treated
as indicated in the Results section, and NO2
/NO3
 levels
were measured using a NOA 280 Nitric Oxide Analyzer.
Reporter gene assay using the 5-flanking region of the
human eNOS gene stably transfected into EA.hy 926
cells. The EA.hy 926 cells stably transfected with the
plasmid p-eNOS-Hu-3500-Luc-neo have been described
previously (11,12). Extracts from treated cells were prepared
using passive lysis buffer (Promega), and luciferase activities
were determined using the luciferase assay system as de-
scribed (11,12).
Transient transfection of EA.hy 926 cells and reporter
gene assays. The EA.hy 926 cells were transfected with
luciferase constructs containing human eNOS promoter
fragments of various lengths (0.9 g of p-eNOS-1600-Hu-
Luc, p-eNOS-1111-Hu-Luc, p-eNOS-633-Hu-Luc or
p-eNOS-326-Hu-Luc) using SuperFect (Qiagen). The
plasmid pRL-SV40 (containing the renilla-luciferase gene
driven by an SV40 promoter) was co-transfected for nor-
malization. The luciferase- and renilla-luciferase-activities
of the extracts were determined using the Dual-Luciferase
System (Promega).
Electrophoretic mobility shift assays. Binding activities of
transcription factors GATA, Sp1/Sp3, PEA3, YY1, and
Elf-1 in nuclear extracts from ethanol- or red-wine–treated
cells were determined by electrophoretic mobility shift
assays as described (11,14). Double-stranded oligonucleo-
tides containing the following transcription factor binding
motifs of the human eNOS promoter were used: Sp1-
binding motif (positions 95 to 104), Sp1/Sp3-like-
binding motif (positions 141 to 146), GATA-binding
motif (positions 225 to 230), PEA3-binding motif
(positions 24 to 40), YY1-binding motif (positions
117 to121) or the Elf-1-binding motif (positions126
to 129). The DNA-protein complexes were analyzed on
polyacrylamide gels. The dried gels were autoradiographed
on X-ray film.
Statistics. Statistical differences between mean values were
determined by analysis of variance (ANOVA) followed by
the Fisher PLSD test for comparison of means, or by the
Student t test for unpaired data (as indicated in the figure
legends).
RESULTS
Upregulation of eNOS mRNA expression by different
red wines in human endothelial cells. Human EA.hy 926
endothelial cells were incubated for 24 h with three different
German red wines (“Dornfelder”, “Kriegsheimer Rosengar-
ten”, and “Spa¨tburgunder”), or six different French red
wines (“Ch.Bonnet reserve”, “Ch.Bellegrave”, “Ch.Mare-
chaude”, “Ch.Cabieres”, “Ch.Rousseau”, and “L.Cheva-
liers”). The red wines were diluted in the cell culture
medium to a final concentration of 10% (v/v). Cells receiv-
ing no treatment, or cells exposed to ethanol 1.25% (v/v) in
the cell culture medium, served as controls. Cells treated
with the different German red wines showed only a mod-
erate increase in eNOS mRNA expression, whereas cells
exposed to the French red wines showed a significant
Abbreviations and Acronyms
eNOS  endothelial-type nitric oxide synthase
GAPDH  glyceraldehyde-3-phosphate dehydrogenase
HUVEC  human umbilical vein endothelial cells
mRNA  messenger ribonucleic acid
NO  nitric oxide
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enhancement of eNOS mRNA (up to fourfold, Fig. 1). The
effect of French red wine on eNOS mRNA expression was
confirmed with primary HUVECs (Fig. 2). Incubation of
these cells with the French red wine “L.Chevaliers” led to a
similar increase in eNOS mRNA expression as seen in
EA.hy 926 cells. To test whether the upregulation of eNOS
by French red wines was influenced by the way the wine is
produced, we tested two different “Ch.Bonnet,” one ma-
tured in new oak barrels (“en barrique”) and one matured in
steel tanks (“non-barrique”). In EA.hy 926 cells, no signif-
Figure 1. Effect of red wines on endothelial-type nitric oxide synthase (eNOS) messenger ribonucleic acid (mRNA) expression in human endothelial EA.hy
926 cells. Cells were left untreated (control, Co) or exposed for 24 h to ethanol (EtOH-Co, 1.25%, v/v), three different German red wines (“Dornfelder”,
“Kriegsheimer Rosengarten”, and “Spa¨tburgunder”) or six different French red wines from Bordeaux (“Ch.Bonnet reserve”, “Ch.Bellegrave”, and
“Ch.Marechaude”), Rhone (“Ch.Cabieres”), and Burgundy (“Ch.Rousseau”, “L.Chevaliers”). The red wines were diluted in the cell culture medium to a
final concentration of 10% (v/v). RNase protection analyses were performed using antisense RNA probes to human eNOS and GAPDH (for
standardization). The figure shows densitometric analyses of three different gels. Bars represent means  SEM. Asterisks indicate significant differences
from untreated cells (***p  0.001; by ANOVA followed by the Fisher PLSD test).
Figure 2. Upregulation of endothelial-type nitric oxide synthase (eNOS) messenger ribonucleic acid (mRNA) by the French red wine “L.Chevaliers” in
human umbilical vein endothelial cells (HUVEC). The eNOS mRNA expression was quantified with RNase protection assay. Ribonucleic acids were
prepared from HUVEC cells incubated either for 24 h with ethanol (EtOH-Co, 1.25%, v/v) or with the red wine “L.Chevaliers” (L. Chev., 10% v/v). The
left panel shows an autoradiograph of a representative gel of an RNase protection experiment. T: tRNA control; N: eNOS antisense probe alone; G:
GAPDH antisense probe alone; M: molecular weight markers. The right panel shows densitometric analyses of three different gels. Bars represent means
 SEM. Asterisks indicate significant differences from ethanol-treated cells (***p  0.001; by the Student t test for unpaired data).
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icant difference in the upregulation of eNOS mRNA
expression could be detected. “Ch.Bonnet reserve” produced
“en barrique” (10%, v/v, 24 h) generated an upregulation to
226%  17% of the ethanol control and “Ch.Bonnet”
produced “non-barrique” (10%, v/v, 24 h) upregulated
eNOS expression to 207%  13% (means  SEM, n  4,
each).
Concentration- and time-dependent upregulation of
eNOS mRNA expression by French red wines in human
EA.hy 926 endothelial cells. The EA.hy 926 cells were
incubated for 24 h with different concentrations (1%, 3%,
and 10%, v/v) of red wine, or with 1.25% (v/v) ethanol as
the control. Then, total RNA was prepared. As shown in
Figure 3A, the French red wines (“Ch.Bonnet reserve” and
“L.Chevaliers”) increased eNOS mRNA expression in a
concentration-dependent manner, whereas the German red
wine (“Dornfelder”) showed only a small, nonsignificant
enhancement of eNOS mRNA expression. Figure 3B dem-
onstrates that the stimulation of eNOS expression by
French red wine (“Ch.Bonnet reserve”) is a function of
concentration and time; high concentrations (10%, v/v)
produced significant increases already after 12 h; lower
concentrations (1%, v/v) required up to 10 days of incuba-
tion to reach a similar degree of stimulation.
Figure 3. Concentration- and time-dependent upregulation of endothelial-type nitric oxide synthase (eNOS) messenger ribonucleic acid (mRNA)
expression by French red wines. The eNOS mRNA expression was quantified with RNase protection assay. (A) EA.hy 926 cells were incubated for 24 h
with ethanol (EtOH-Co, 1.25%, v/v), a German (“Dornfelder”) and two French red wines (“L.Chevaliers” and “Ch.Bonnet reserve”) diluted to final
concentrations of 1%, 3%, and 10% (v/v). (B) Cells were exposed to cell culture medium containing 1%, 3%, and 10% (v/v) of “Ch.Bonnet reserve” for
different periods of time. Symbols represent means  SEM. Asterisks indicate significant differences from ethanol-treated cells at the same time points
(*p  0.05; **p  0.01; ***p  0.001; by ANOVA followed by the Fisher PLSD test).
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Concentration-dependent upregulation of eNOS protein
and eNOS activity by French red wines in human EA.hy
926 endothelial cells. As shown in Figure 4A, French red
wines increased eNOS protein expression in EA.hy 926
cells in a concentration-dependent fashion. Densitometric
analyses of the eNOS protein bands indicated an increase to
140  15, 182  11, and 210  17% for “Ch.Bonnet
reserve” and 130  13, 160  14, and 224  12% for
“L.Chevaliers” compared to ethanol-treated cells.
Also, NO production by EA.hy 926 cells (measured with
RFL-6 reporter cell assay) was increased in a concentration-
dependent manner after treatment with French red wines
for 48 h (Fig. 4B). In additional experiments, eNOS activity
was determined by measuring NO2
/NO3
. Ethanol-
treated EA.hy 926 cells (1.25%, v/v, 48 h) produced 3.7 
1.0 pmol NO2
/g protein after a 10-min stimulation with
calcium ionophore A23187 (10 mol/liter). Incubation of
EA.hy 926 cells with 1%, 3%, or 10% (v/v) “Ch.Bonnet
reserve” for 48 h enhanced the calcium ionophore-
stimulated NO2
 production to 4.3  0.2, 4.8  0.3, and
6.3  0.5 pmol/g protein. Incubation with “L.Chevaliers”
(1%, 3%, or 10%, v/v) increased the activity to 6.6 1.0, 7.1
 0.9, and 10.0  1.3 pmol/g protein (n  3, each).
Concentration-dependent upregulation of eNOS pro-
moter activity by French red wines in human EA.hy 926
endothelial cells. To analyze the effect of French red wines
on eNOS promoter activity, EA.hy 926 cells were stably
transfected with the plasmid p-eNOS-3500-Hu-Luc-neo.
When these cells were incubated for 24 h with the two
French red wines “Ch.Bonnet reserve” and “L.Chevaliers”
(1%, 3%, and 10%, v/v), the activity of the eNOS promoter
was increased in a concentration-dependent manner. The
increase reached 2.9-fold for “Ch.Bonnet reserve” and
3.3-fold for “L.Chevaliers” compared with ethanol-treated
control cells (Fig. 5A).
In further experiments, EA.hy 926 cells were transiently
transfected with different pGl3-Basic-derived constructs
containing fragments of 1.6-kb to 0.33-kb of the human
eNOS promoter cloned before a luciferase reporter gene.
The 1.6-kb-eNOS-promoter-luciferase construct showed a
significant (7.5-fold) increase in (basal) promoter activity
compared with pGl3-Basic. The nonstimulated activities of
the shorter promoter fragments did not differ significantly
from those of p-eNOS-1600-Hu-Luc: p-eNOS-1111-Hu-
Luc had 118%  21% of p-eNOS-1600-Hu-Luc,
p-eNOS-633-Hu-Luc 78% 20%, and p-eNOS-326-Hu-
Luc 143%  37% (n  3, each). The transfected cells were
incubated for 24 h with either ethanol (1.25%, v/v) or the
French wine “L.Chevaliers” (10%, v/v). The wine increased
the activities of the 1.6-kb-, 1.1-kb-, and the 0.6-kb-
promoter fragments more than 2.5-fold; the activity of the
0.3-kb-promoter fragment was still increased 1.7-fold (Fig.
5B).
Using electrophoretic mobility shift assay, we tested the
effect of the red wines “Ch.Bonnet reserve” and “L.Cheva-
liers” on the binding activities of transcription factors
known to be important for the activity of the human eNOS
promoter. We incubated nuclear extracts from ethanol- or
red-wine–treated cells with oligonucleotides containing
transcription factor binding motifs of the human eNOS
promoter for Sp1, Sp1/Sp3-like, GATA, PEA3, YY1, and
Elf-1 as previously described (11,14). However, no wine-
Figure 4. Effect of French red wines on endothelial-type nitric oxide
synthase (eNOS) protein expression and eNOS activity in EA.hy 926 cells.
(A) Western blot analyses using a polyclonal anti-eNOS- and a monoclo-
nal anti--tubulin-antibody (for normalization). Cells were incubated for
48 h with ethanol (EtOH-Co, 1.25%, v/v) or two different French red
wines (“Ch.Bonnet reserve” and “L.Chevaliers”, 1%, 3%, and 10%, v/v).
The blots represent four independent experiments each. (B) This panel
shows the effect of a 48-h incubation with “L.Chevaliers” and “Ch.Bonnet
reserve” on the nitric oxide (NO) production in EA.hy 926 cells stimulated
for 2 min with the calcium ionophore A23187. Conditioned medium from
EA.hy 926 cells was transferred to RFL-6 reporter cells and incubated for
2 min. Thereafter, cGMP content in RFL-6 cells was determined by
radioimmunoassay. Basal cGMP content of the RFL-6 cells (1.7  0.16
pmol/106 cells) was subtracted from all samples. The NO production of
ethanol-treated EA.hy 926 cells (EtOH-Co, 13.1 0.19 pmol cGMP/106
RFL-6 cells) was set 100%. Data represent means  SEM of three
independent experiments. Asterisks indicate significant differences from
ethanol-treated cells (*p  0.05; **p  0.01; by ANOVA followed by the
Fisher PLSD test).
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induced change in binding activity could be detected for
any of these transcription factors (n  4 each, data not
shown).
Enhancement of eNOS mRNA stability by French red
wine. As shown in Figure 6, eNOS mRNA levels in
ethanol (1.25%, v/v)-treated EA.hy 926 cells declined over
time after treatment with the transcription inhibitor actino-
mycin D. The apparent half-life was about 30 h. Treatment
of EA.hy 926 cells with “Ch.Bonnet reserve” significantly
increased the stability of the eNOS mRNA.
DISCUSSION
The current study provides evidence that red wines from
France (and probably other locations) can upregulate the
eNOS gene in human endothelial cells. This upregulation
was seen in both EA.hy 926 cells and primary HUVEC.
The enhanced mRNA and protein expression resulted in an
increased production of bioactive NO, as measured by the
RFL-6 reporter cell assay. Recent studies have indicated
that an upregulation of eNOS under certain pathophysio-
Figure 5. Enhancement of endothelial-type nitric oxide synthase (eNOS) promoter activity in EA.hy 926 cells after incubation with French red wines. (A)
EA.hy 926 cells were stably transfected with p-eNOS-3500-Hu-Luc-neo. Stable cells were incubated for 24 h with ethanol (EtOH-Co, 1.25%, v/v), or
various concentrations of two French red wines (“L.Chevaliers” and “Ch.Bonnet reserve”). The luciferase activity (normalized by protein content) was taken
as a measure of eNOS promoter activity. Bars represent means  SEM of three independent experiments. Asterisks indicate significant differences from
ethanol-treated cells (**p  0.01; ***p  0.001; by ANOVA followed by the Fisher PLSD test). (B) EA.hy 926 cells were transiently transfected with
pGl3-Basic (containing a promoterless luciferase gene) or different eNOS promoter luciferase constructs (p-eNOS-1600-Hu-Luc, p-eNOS-1111-Hu-Luc,
p-eNOS-633-Hu-Luc, and p-eNOS-326-Hu-Luc, containing 1.6-kb to 0.33-kb of the eNOS promoter cloned before a luciferase reporter gene). The
different transfected cells were either exposed 24 h to ethanol (EtOH-Co, 1.25%, v/v) or to the red wine “L.Chevaliers” (10%, v/v). The relative luciferase
activity (corrected with renilla-luciferase activity; see Methods) was taken as a measure of eNOS promoter activity. Data represent means  SEM of three
independent experiments.
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logical conditions can go along with a dysfunctional enzyme
(15,16). However, the current study provides no evidence
for a dysfunction of eNOS induced by red wine.
Vasoprotective role of NO. In addition to its vasodilator
properties, NO can convey vasoprotection in several ways.
Nitric oxide released toward the vascular lumen is a potent
inhibitor of platelet aggregation and adhesion to the vascu-
lar wall (17,18). Besides protection from thrombosis, this
also prevents the release of platelet-derived growth factors
that stimulate smooth muscle proliferation and its produc-
tion of matrix molecules. Endothelial NO also controls the
expression of genes involved in atherogenesis. Nitric oxide
decreases the expression of the chemoattractant protein
MCP-1 (19), and of surface adhesion molecules such as
CD11/CD18 (20), P-selectin (21), vascular cell adhesion
molecule-1 (VCAM-1) (22), and intercellular adhesion
molecule-1 (ICAM-1) (23), thereby preventing leukocyte
adhesion to vascular endothelium and leukocyte migration
into the vascular wall. This offers protection against an early
phase of atherogenesis. Also, the decreased endothelial
permeability, the reduced influx of lipoproteins into the
vascular wall (24), and the inhibition of LDL oxidation (25)
may contribute to the anti-atherogenic properties of NO.
Furthermore, NO has been shown to inhibit DNA synthe-
sis, mitogenesis, and proliferation of vascular smooth muscle
cells (26,27) as well as smooth muscle cell migration (28),
thereby protecting against a later phase of atherogenesis.
Based on the combination of those effects, NO produced in
endothelial cells can be considered an anti-atherosclerotic
principle (29).
Effects of red wine on the endothelial NO system. Pre-
vious evidence in the published data already suggested an
interaction of red wine with the endothelial NO system.
Red wine or extracts obtained from red wine caused
endothelium-dependent, NO-mediated vasorelaxation of
rat or rabbit aorta preconstricted with norepinephrine (30–
32). Also, in human coronary arteries and rat aortic rings in
vitro, short-term incubation with red wine induced an
endothelium-dependent vasodilation and an increased vas-
cular cGMP content (10). These rapid effects of red wine
are likely to involve an acute activation of eNOS (30–32).
The molecular mechanisms of this acute enzyme activation
are unknown, but they are most probably unrelated to the
gene-regulatory effects described in the current study.
Molecular mechanisms contributing to eNOS upregula-
tion by red wine. The upregulation of eNOS expression by
red wine is brought about by both transcriptional and
posttranscriptional (mRNA-stabilizing) events. The pre-
dominant transcriptional component seems to involve an
activation of rather proximal portions of the eNOS pro-
moter (first 326 bp), because the transcriptional stimulation
by red wine was largely preserved with this short promoter
fragment (Fig. 5B). This fragment is the binding target of a
number of transcription factors, such as Sp1, GATA,
PEA3, YY1, and Elf-1, whose functional relevance has been
demonstrated previously (for review see Li et al. [33]). In
the current study, we performed electromobility shift assays
with nuclear extracts from ethanol (1.25%, v/v)-treated,
compared with red-wine–treated cells. No wine-induced
changes in protein-DNA binding was found with oligonu-
cleotides containing the cognate Sp1-, Sp1/Sp3-like,
GATA-, PEA3-, YY1-, or Elf-1-binding motifs of the
proximal human eNOS promoter. This suggests that the
transcriptional activation caused by red wines is unlikely to
be based on the activation of one of the above transcription
factors. Rather, it may be a multifactorial process and/or
involve yet unidentified transcription factor(s).
Ingredients of grapes are responsible for eNOS upregu-
lation. Moderate alcohol intake, also from beverages other
than wine, has been shown to lower the risk of cardiovas-
cular disease (4–6). However, the ethanol content of red
wine is unlikely to be responsible for the upregulation of
eNOS expression observed here, because the equivalent
amount of ethanol (1.25%, v/v) alone produced only a
marginal upregulation of eNOS (Fig. 1), and all subsequent
experiments (Figs. 2–6) were performed with appropriate
ethanol controls. In addition, German red wines (which
were largely ineffective) and French red wines have the same
alcohol content.
Also, no difference was detected between “en barrique”
and “non-barrique”-produced red wines made from the
same grapes, suggesting that the compounds stimulating
eNOS expression derive from the grapes rather than the
barrel staves. The numerous phenolic acids, polyphenols,
and flavonoids contained in red wine are likely candidates,
probably mediating the expressional upregulation of eNOS.
Figure 6. Effect of French red wine on endothelial-type nitric oxide
synthase (eNOS) messenger ribonucleic acid (mRNA) stability. The
EA.hy 926 cells were preincubated either with ethanol (EtOH-Co, 1.25%,
v/v) or with the red wine “Ch.Bonnet reserve” (10%, v/v) for 24 h. To
inhibit transcription, actinomycin D (20 g/ml) was added to the culture
medium. Ribonucleic acid was prepared 0, 12, 24, and 36 h thereafter. The
eNOS mRNA expression was determined by RNase protection assay. The
eNOS mRNA levels in both groups at the time of addition of actinomycin
D (0 h) were set at 100%. Circles represent means  SEM of the
densitometric analyses of four different gels. Asterisks indicate significant
differences from ethanol-treated cells at the same time points (**p  0.01;
***p  0.001; by the Student t test for unpaired data).
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Differences in the content of these compounds between
wines (34,35) could explain why French wines were partic-
ularly effective in stimulating eNOS expression. French red
wines contain high polyphenol levels compared with wines
from other regions (34,35).
Conclusions. This study provides evidence that red wine
can stimulate the expression of the eNOS gene leading to an
enhanced production of bioactive NO. In concert with other
systemic beneficial effects of red wine, this could contribute
to the cardiovascular protection enjoyed by moderate drink-
ers of red wine.
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